We aimed to investigate the prevalence of TERT promoter and ALK mutations in thyroid cancer patients with a high prevalence of the BRAF V600E mutation and their potential contribution for the risk stratification of these patients. This evidence concerns the gene BRAF and thyroid gland carcinoma.